Shattuck Labs Shares Rise Over 4% After JPMorgan Analyst Issues Buy Rating
On July 24, Shattuck Labs (NASDAQ: STTK) saw its stock rise nearly 5%, driven by a new analyst report from Brian Cheng of J.P. Morgan. The clinical-stage biotech received an 'overweight' rating with a price target of $10 per share — representing potential upside of about 35% over the recent closing level. Cheng's analysis focused on Shattuck’s lead drug candidate, SL-325, which is being developed for inflammatory bowel disease. The analyst highlighted positive data from clinical trials showing a favorable safety profile and strong target engagement compared to similar drugs in development. Although still early-stage, the compound is set to enter Phase 2 trials later this year. The Motley Fool noted that while Shattuck Labs was not included on its latest list of top stock picks for investors, it remains an active area of interest due to continued momentum and potential regulatory pathways.
Tickers: $JPM
Topics: analyst_ratings biotech clinical_trials